In a phase 2 trial in participants with obesity and MASLD, once-weekly treatment with the GIP/GLP-1/GCG triple agonist retatrutide resulted in substantial reductions in liver fat, body weight, abdominal visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (ASAT), serum lipids
If you experience severe, persistent abdominal pain while taking a GLP-1 receptor agonist, seek urgent medical attention
Download our GLP-1 app to Turn Your Weight Loss Journey into Your Favorite Game How Long Can You Take GLP-1
What to know about retatrutide
For those researching cellular energy and metabolism, understanding the optimal 5 amino 1 mq dosing is critical for studying its effects on NAD+ levels and mitochondrial activity
IN-VITRO LABORATORY RESEARCH : To the extent there is any information contained on the Website, it is strictly for the sole purposes of in-vitro laboratory research